Ian Arnott

13.0k total citations · 2 hit papers
132 papers, 5.4k citations indexed

About

Ian Arnott is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Ian Arnott has authored 132 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Genetics, 75 papers in Epidemiology and 49 papers in Surgery. Recurrent topics in Ian Arnott's work include Inflammatory Bowel Disease (103 papers), Microscopic Colitis (67 papers) and Helicobacter pylori-related gastroenterology studies (16 papers). Ian Arnott is often cited by papers focused on Inflammatory Bowel Disease (103 papers), Microscopic Colitis (67 papers) and Helicobacter pylori-related gastroenterology studies (16 papers). Ian Arnott collaborates with scholars based in United Kingdom, United States and Netherlands. Ian Arnott's co-authors include Jack Satsangi, Charlie W. Lees, Hazel E. Drummond, Gwo‐Tzer Ho, Elaine R. Nimmo, Richard Driscoll, Craig Mowat, Tariq Ahmad, Marian C. Aldhous and Subrata Ghosh and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Gut.

In The Last Decade

Ian Arnott

121 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the management of inflammatory bowel disease in adults

2011 1.0k citations Craig Mowat, Ian Arnott et al. Gut profile →
Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease

2008 659 citations Johan Van Limbergen, Richard K. Russell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian Arnott United Kingdom	36	4.0k	3.1k	1.9k	1.0k	544	132	5.4k
Jean‐Louis Dupas France	32	3.5k 0.9×	3.0k 1.0×	2.0k 1.1×	876 0.9×	466 0.9×	112	5.4k
Simon Lichtiger United States	25	5.3k 1.3×	4.1k 1.4×	2.0k 1.1×	1.4k 1.4×	665 1.2×	64	6.9k
Alain Bitton Canada	45	4.6k 1.1×	3.4k 1.1×	2.3k 1.2×	1.4k 1.4×	592 1.1×	203	7.1k
David Laharie France	42	3.8k 0.9×	3.4k 1.1×	1.7k 0.9×	1.0k 1.0×	435 0.8×	207	5.8k
Neeraj Narula Canada	32	3.2k 0.8×	2.5k 0.8×	1.6k 0.8×	740 0.7×	455 0.8×	192	4.5k
Manuel Barreiro‐de Acosta Spain	29	3.5k 0.9×	2.7k 0.9×	1.5k 0.8×	602 0.6×	369 0.7×	227	4.6k
Milan Lukáš Czechia	33	4.3k 1.1×	3.2k 1.1×	1.6k 0.8×	1.9k 1.9×	350 0.6×	156	6.0k
Walter Reinisch Austria	32	5.3k 1.3×	4.1k 1.3×	2.0k 1.1×	1.8k 1.8×	538 1.0×	71	7.2k
Pia Munkholm Denmark	35	3.9k 1.0×	2.8k 0.9×	1.8k 0.9×	669 0.7×	438 0.8×	72	5.3k
María Chaparro Spain	38	3.5k 0.9×	2.7k 0.9×	1.5k 0.8×	1.2k 1.2×	255 0.5×	251	5.4k

Countries citing papers authored by Ian Arnott

Since Specialization

Citations

This map shows the geographic impact of Ian Arnott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Arnott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Arnott more than expected).

Fields of papers citing papers by Ian Arnott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Arnott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Arnott. The network helps show where Ian Arnott may publish in the future.

Co-authorship network of co-authors of Ian Arnott

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Arnott. A scholar is included among the top collaborators of Ian Arnott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Arnott. Ian Arnott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gros, Beatriz, Nikolas Plevris, Mathew Lyons, et al.. (2025). Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland. Alimentary Pharmacology & Therapeutics. 62(7). 699–709.

Gros, Beatriz, J D Kennedy, Colin Noble, et al.. (2024). Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison. Journal of Crohn s and Colitis. 19(7).

Gros, Beatriz, Nikolas Plevris, Colin Noble, et al.. (2023). Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis. Journal of Crohn s and Colitis. 19(1). 13 indexed citations

Gros, Beatriz, Nikolas Plevris, Mathew Lyons, et al.. (2023). Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort. United European Gastroenterology Journal. 11(2). 179–188. 12 indexed citations

Jones, Gareth‐Rhys, Nikolas Plevris, Hayley Hutchings, et al.. (2023). Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset. Journal of Crohn s and Colitis. 18(2). 286–290. 1 indexed citations

Akbar, Ayesha, Ian Arnott, Nicholas A. Kennedy, et al.. (2021). Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. British Journal of Hospital Medicine. 82(10). 1–11. 2 indexed citations

Arnott, Ian, et al.. (2021). PMO-22 Investigating Iron deficiency anaemia in the inflammatory bowel disease population in lothian, scotland. A88.1–A88.

Jones, Gareth‐Rhys, et al.. (2021). P109 Vedolizumab is an effective treatment for antibiotic refractory chronic pouchitis. A98.1–A98.

Plevris, Nikolas, Philip Jenkinson, Mathew Lyons, et al.. (2018). DOP072 Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s disease cohort. Journal of Crohn s and Colitis. 12(supplement_1). S079–S080.

10.

Arnott, Ian, Craig Mowat, Holly Ennis, et al.. (2016). OP026. The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn’s disease following surgical resection in 240 patients. Journal of Crohn s and Colitis. 10(suppl 1). S21–S22. 2 indexed citations

11.

Kennedy, Nicholas A., Nicola C. Hare, Gwo‐Tzer Ho, et al.. (2012). PTU-123 Acute severe ulcerative colitis: the last 12 years in Edinburgh: Abstract PTU-123 Figure 1. Gut. 61(Suppl 2). A235.2–A236. 2 indexed citations

12.

Ha, Sy, et al.. (2012). PWE-244 Does thromboprophylaxis in ulcerative colitis work?: data from the UK IBD audit. Gut. 61(Suppl 2). A397.2–A397.

13.

Kennedy, Nicholas A., et al.. (2012). PMO-226 Differing phenotype in elderly IBD; should Montreal include an A4 category. Gut. 61(Suppl 2). A166.2–A166. 2 indexed citations

14.

Arnott, Ian, et al.. (2012). OC-165 No increase in surgical complication in patients treated with rescue therapy for acute severe ulcerative colitis: data from the UK IBD audit. Gut. 61(Suppl 2). A71.1–A71. 2 indexed citations

15.

Arnott, Ian, et al.. (2012). PWE-228 An assessment of the impact 5ASA dose, dose interval, preparation and delivery have on maintaining remission in ulcerative colitis. Gut. 61(Suppl 2). A391.1–A391. 1 indexed citations

16.

Kennedy, Nicholas A., et al.. (2012). OC-166 Predictive factors of disease relapse following thiopurine withdrawal for sustained clinical remission of IBD: Abstract OC-166 Figure 1. Gut. 61(Suppl 2). A71.2–A72. 1 indexed citations

17.

Walkden, Andrew, Robin Dart, Kathleen Kingstone, et al.. (2010). OC-013 Clinical utility of faecal calprotectin in diagnosing inflammatory bowel disease during first presentation to the gastroenterology clinic: a novel investigative algorithm. A6.1–A6. 1 indexed citations

18.

Aldhous, Marian C., Hazel E. Drummond, Niall Anderson, et al.. (2007). Does Cigarette Smoking Influence the Phenotype of Crohn's Disease? Analysis Using the Montreal Classification. The American Journal of Gastroenterology. 102(3). 577–588. 85 indexed citations

19.

Limbergen, Johan Van, Richard K. Russell, Elaine R. Nimmo, et al.. (2007). Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohnʼs disease in Northern Europe. Inflammatory Bowel Diseases. 14(3). 338–346. 48 indexed citations

20.

Limbergen, Johan Van, Richard K. Russell, Elaine R. Nimmo, et al.. (2006). Genetics of the innate immune response in inflammatory bowel disease. Inflammatory Bowel Diseases. 13(3). 338–355. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact